AMETEK (AME) Q1 2026 earnings review
Record Orders and Margin Expansion Drive Strong Q1 and Raised Guidance
AMETEK delivered an outstanding Q1 2026, with an 11% YoY increase in sales to $1.93B and a 13% jump in Adjusted EPS to $1.97. The standout metric was a 23% surge in orders, resulting in a record backlog that validates the end of the recent destocking cycle and a broad-based market recovery. The Electromechanical Group (EMG) led the charge with a 33% operating profit increase and a 380 basis point margin expansion. Management demonstrated strong operational control by raising the full-year Adjusted EPS guidance to $7.94-$8.14, signaling confidence in their ability to integrate recent acquisitions and convert their record backlog into earnings.
🐂 Bull Case
A 23% spike in Q1 orders built a record backlog, providing excellent revenue visibility for the remainder of 2026 and proving that end-market demand is accelerating across the board.
The Electromechanical Group posted a 380 bps operating margin expansion, driven by robust organic sales growth and the successful recovery of the Paragon Medical business.
🐻 Bear Case
Recent large acquisitions, such as Faro Technologies and LKC Technologies, carry lower initial margins and require significant operational execution to reach AMETEK's 30% EBITDA target.
With the destocking cycle firmly in the rearview mirror, AMETEK will face increasingly difficult year-over-year comparables in H2 2026, which may naturally decelerate growth rates.
⚖️ Verdict: 🟢
Bullish. AMETEK is firing on all cylinders. The combination of double-digit revenue growth, massive order intake, and structural margin expansion in the EMG segment creates a highly compelling growth narrative that supports the raised full-year guidance.
Key Themes
Record Order Intake Signals Broad Recovery
Orders skyrocketed 23% YoY in Q1, driving the company's backlog to a record high. This is a dramatic acceleration from the 8% order growth seen in the same quarter last year. The surge indicates that the post-pandemic destocking cycle is fully over and that underlying industrial, automation, and aerospace demand is robust.
EMG Margins Achieving Structural Shift
The Electromechanical Group (EMG) delivered an exceptional quarter, with sales up 13% to $663.9M and operating income up 33% to $170.8M. Operating margins expanded by a massive 380 basis points to 25.7%. This accelerates the recovery seen in late 2025, heavily driven by the Paragon Medical turnaround and normalization in Automation markets.
Aggressive Capital Deployment and M&A Integration
AMETEK continues to use strategic acquisitions as a primary growth lever. The recent integrations of Faro Technologies, Kern Micro Technique, and the newly acquired LKC Technologies are driving top-line growth. Management's playbook involves acquiring lower-margin technology leaders and implementing operational excellence to double their EBITDA margins over a three-year horizon.
Process Segment Recovery Trajectory
While overall company orders were phenomenal, previous quarters highlighted sluggishness in the Electronic Instruments Group's (EIG) process businesses due to customer hesitation and trade uncertainties. EIG operating margins expanded by a modest 40 basis points to 31.4%, lagging the explosive profitability growth seen in the EMG segment. Monitoring the organic growth specifically within the process sub-segment remains critical.
Macroeconomic and Tariff Complexities
Despite management's proven ability to offset inflation and tariffs through pricing and supply chain localization, the global trade environment remains a persistent risk. The company previously navigated a $100M direct annual tariff impact; any further escalations in US-China trade relations could introduce new volatility to project-based revenues.
Other KPIs
Up 6% YoY. Sales grew 11% to $1.26 billion, driven by solid organic growth and recent acquisitions. Core margins improved by 40 basis points to 31.4%, demonstrating stable execution despite the dilutive impact of absorbing newer, lower-margin acquisitions into the segment.
Up 160 basis points YoY from 26.3% in 25Q1. This robust core margin expansion proves that AMETEK's pricing power is effectively outpacing inflation and integration costs, allowing volume growth to drop cleanly to the bottom line.
Guidance
Decelerating slightly. The midpoint ($1.98) represents an 11% YoY increase over 25Q2 ($1.78), a modest step down from the 13% growth achieved in 26Q1, but still indicating strong double-digit momentum.
Stable. Follows the ~11% growth seen in 26Q1 and aligns with the expected baseline growth as the company starts to hit tougher year-over-year comparables from the late-2025 recovery.
Accelerating vs prior expectations. Raised from the previous outlook of $7.87-$8.07. The new midpoint ($8.04) implies an 8.2% YoY growth rate compared to FY25's $7.43, driven by the massive order intake and margin expansion realized in Q1.
Accelerating from prior long-term trends. A notable shift upward from the 'mid-to-high single digits' language used at the end of 2025, heavily derisked by the 23% order growth and record backlog.
Key Questions
Order Conversion Timeline
With orders up an impressive 23% in Q1, how quickly does management expect this record backlog to convert into revenue, and are there any supply chain constraints limiting immediate throughput?
Faro and LKC Integration Status
Given the target of doubling Faro's EBITDA margins within three years, what specific operational milestones were achieved this quarter, and how is the new LKC Technologies acquisition expected to impact EIG margins in the near term?
Process Segment Health
While overall demand is surging, is the Process segment fully participating in this 23% order growth, or are project delays and trade-related hesitancy still suppressing its specific trajectory?